- Home
- ACIC vs PCRX Comparison
ACIC vs PCRX Comparison
Compare ACIC & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIC
- PCRX
- Stock Information
- Founded
- ACIC 1999
- PCRX 2006
- Country
- ACIC United States
- PCRX United States
- Employees
- ACIC N/A
- PCRX N/A
- Industry
- ACIC Property-Casualty Insurers
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- ACIC Finance
- PCRX Health Care
- Exchange
- ACIC Nasdaq
- PCRX Nasdaq
- Market Cap
- ACIC 588.1M
- PCRX 1.2B
- IPO Year
- ACIC N/A
- PCRX 2011
- Fundamental
- Price
- ACIC $11.92
- PCRX $26.59
- Analyst Decision
- ACIC Buy
- PCRX Buy
- Analyst Count
- ACIC 1
- PCRX 10
- Target Price
- ACIC $16.00
- PCRX $29.30
- AVG Volume (30 Days)
- ACIC 156.1K
- PCRX 892.8K
- Earning Date
- ACIC 02-27-2025
- PCRX 02-27-2025
- Dividend Yield
- ACIC 4.18%
- PCRX N/A
- EPS Growth
- ACIC N/A
- PCRX N/A
- EPS
- ACIC 1.76
- PCRX N/A
- Revenue
- ACIC $290,784,000.00
- PCRX $694,957,000.00
- Revenue This Year
- ACIC N/A
- PCRX $5.14
- Revenue Next Year
- ACIC $12.68
- PCRX $2.44
- P/E Ratio
- ACIC $6.77
- PCRX N/A
- Revenue Growth
- ACIC 1.02
- PCRX 4.40
- 52 Week Low
- ACIC $8.82
- PCRX $11.16
- 52 Week High
- ACIC $15.08
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- ACIC 38.97
- PCRX 77.75
- Support Level
- ACIC $11.81
- PCRX $25.06
- Resistance Level
- ACIC $12.66
- PCRX $27.10
- Average True Range (ATR)
- ACIC 0.32
- PCRX 1.45
- MACD
- ACIC 0.00
- PCRX 0.28
- Stochastic Oscillator
- ACIC 10.38
- PCRX 86.23
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.